These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16515968)

  • 1. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Lohse C; Novara G; Pea M; Cavalleri S; Artibani W
    J Urol; 2006 Apr; 175(4):1235-9. PubMed ID: 16515968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.
    Ficarra V; Novara G; Galfano A; Brunelli M; Cavalleri S; Martignoni G; Artibani W
    BJU Int; 2009 Jan; 103(2):165-70. PubMed ID: 18782313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
    J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
    Parker AS; Kosari F; Lohse CM; Houston Thompson R; Kwon ED; Murphy L; Riehle DL; Blute ML; Leibovich BC; Vasmatzis G; Cheville JC
    Cancer; 2006 Jul; 107(1):37-45. PubMed ID: 16736510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.
    Thompson RH; Leibovich BC; Lohse CM; Cheville JC; Zincke H; Blute ML; Frank I
    J Urol; 2007 Feb; 177(2):477-80. PubMed ID: 17222614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
    Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
    J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.
    Webster WS; Lohse CM; Thompson RH; Dong H; Frigola X; Dicks DL; Sengupta S; Frank I; Leibovich BC; Blute ML; Cheville JC; Kwon ED
    Cancer; 2006 Jul; 107(1):46-53. PubMed ID: 16708355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma.
    Pflanz S; Brookman-Amissah S; Roigas J; Kendel F; Hoschke B; May M
    Scand J Urol Nephrol; 2008; 42(6):507-13. PubMed ID: 19031267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of TNM, 2002 version, in localized renal cell carcinoma: is it able to predict different cancer-specific survival probability?
    Ficarra V; Novara G; Galfano A; Novella G; Schiavone D; Artibani W
    Urology; 2004 Jun; 63(6):1050-4. PubMed ID: 15183948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.
    Frank I; Blute ML; Leibovich BC; Cheville JC; Lohse CM; Zincke H
    J Urol; 2005 Jun; 173(6):1889-92. PubMed ID: 15879769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on: External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Giannarini G; Autorino R
    Eur Urol; 2010 Jan; 57(1):109-10. PubMed ID: 19062156
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Blute ML
    Eur Urol; 2010 Jan; 57(1):110-1. PubMed ID: 19062158
    [No Abstract]   [Full Text] [Related]  

  • 17. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.
    Sengupta S; Lohse CM; Leibovich BC; Frank I; Thompson RH; Webster WS; Zincke H; Blute ML; Cheville JC; Kwon ED
    Cancer; 2005 Aug; 104(3):511-20. PubMed ID: 15973740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
    Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
    J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Meisner M; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1878-82. PubMed ID: 17868733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.